VERA

Vera Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1831828Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(300.0M)

EPS (Basic, as reported)

$-4.66

Net Margin FY2025

—

ROE FY2025

-49.6%

Total Equity

$605.0M

Shares Out

72M

Business description

Vera Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (53) → (300)

Fiscal yearFY2020FY2021⚑FY2022⚑FY2023FY2024FY2025

Research & development(45)(22)(69)(78)(126)(215)

General & administrative(4)(12)(22)(24)(41)(100)

Total operating expenses(52)(34)(91)(102)(167)(315)

Operating income(52)(34)(91)(102)(167)(315)

Interest expense00(1)(4)(8)(8)

Interest & investment income00282124

Other income (expense), net(1)2261516

Pre-tax income(53)(33)(89)(96)(152)(300)

Income tax expense000000

Net income(53)(33)(89)(96)(152)(300)

EPS — basic—($2.43)($3.35)($2.25)($2.75)($4.66)

EPS — diluted—($2.43)($3.35)($2.25)($2.75)($4.66)

Shares outstanding — basic (M)—1327435564

Shares outstanding — diluted (M)—1327435564

⚑ Weighted-average shares changed ×2.08 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.59 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.